Navigation Links
InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
Date:9/3/2008

FORT COLLINS, Colo., Sept. 3 /PRNewswire/ -- InVitria (http://www.InVitria.com), a leading global supplier of animal free products that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry, today announced the promotion of Brandy Sargent to Account Manager for the Western United States.

"Brandy has played a vital role in the development and growth of the InVitria's business through her previous roles with the company and we expect her to have an even bigger impact in her new position as Account Manager," said InVitria president Scott Deeter.

Brandy has been with InVitria since 2001, serving in a variety of capacities, including corporate communications and marketing. In her new role, she will work with customer accounts within the biopharmaceutical, cell culture and diagnostics industry located in the Western United States.

"I am very excited about my latest opportunity with InVitria," said Brandy Sargent. "InVitria's animal free product line offers customers a safe, cost-effective way to improve their bioprocessing productivity and product yield. The customer response to our products has been terrific and I am delighted to be working closely with our customers as part of the front-line sales team," said Brandy.

In several studies, InVitria's Cellastim -- a recombinant albumin developed specifically as a cell culture ingredient -- enhances cell growth and productivity better than plasma-derived albumin. Cellastim can supplement chemically defined media as well as traditional media. It has been successfully utilized in CHO, Hybridoma, NSO, Keratinocyte, Fibroblast and primary cell media.

To learn more about InVitria's animal free products, including its recombinant albumin, please email info@InVitria.com.

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim - Cellastim is an albumin used to replace bovine albumin and human albumin as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity by up to 50% when compared with other forms of albumin. Cellastim also has been an effective component in stem cell media and primary cell media.

-- Lacromin - Lacromin has been shown to replace bovine transferrin and human transferrin in cell culture media. In addition, Lacromin is a strong growth promotant as a cell culture ingredient in mammalian cell culture media.

-- Lysobac - Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
2. InVitria Expands Sales Team
3. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
4. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
5. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
6. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
9. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. SAFC Hitech(TM) Plans Further Expansion Into Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses critical ... reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency and ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... San Antonio, TX (PRWEB) , ... February 23, ... ... and Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, ... is indicated for adults at home or in healthcare facilities during periods of ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... studies (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or ... Salivary Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and ...
Breaking Biology Technology:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):